|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||2.2900 - 2.3930|
|52 Week Range||1.9750 - 7.9870|
|Beta (5Y Monthly)||-0.58|
|PE Ratio (TTM)||1.59|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jun 13, 2016|
|1y Target Est||N/A|
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of RBP Global Holdings Ltd and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
It's not possible to invest over long periods without making some bad investments. But you have a problem if you face...
Indivior PLC (LON: INDV) today announced a new research collaboration with Virginia Tech extending the RECOVER (Remission from Chronic Opioid Use-Studying Environmental and Socio-Economic Factors on Recovery) Study ™. RECOVER is a multisite, non-interventional cohort study examining long-term recovery in individuals with moderate to severe opioid use disorder who received at least one dose of study treatment during the SUBLOCADE Phase 3 clinical trials (NCT02357901 and NCT02510014). ¹ The study design and participant characteristics of the RECOVER study can be found in Contemporary Clinical Trials.2 This study will be led by a team of researchers at the Fralin Biomedical Research Institute at Virginia Tech Carilion.
Indivior PLC (LON: INDV) announced today that new analysis from a 12-month investigation of monthly buprenorphine extended-release injections showed that study participants who were treated with SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use (CIII), demonstrated improved or maintained patient-centered outcomes across the following measures:
--Only 20% of people suffering from the disease receive any kind of treatment-- RICHMOND, Va. , Nov. 11, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) announces the launch of a new direct-to-consumer (DTC) ...
SLOUGH, England and RICHMOND, Va., Oct. 31, 2019 /PRNewswire/ -- Indivior PLC (INDV.L) today announced that its Q3/YTD 2019 results press release and investor supplement are now available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com. Key members of Indivior's leadership team led by Shaun Thaxter, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12:00 p.m. BST (8:00 a.m. EDT) on October 31, 2019.
New York and other states have reached a $700 million settlement deal with Reckitt Benckiser over allegations that the drug distributor improperly marketed a drug to treat opioid addiction, New York Attorney General Letitia James said on Wednesday. The deal is a part of an up to $1.4 billion settlement agreed to in July to resolve U.S. state and federal claims that Reckitt Benckiser's former pharmaceuticals business Indivior, before it was spun out, carried out an illegal scheme to boost sales of opioid addiction treatment Suboxone.
RICHMOND, Va., Sept. 26, 2019 /PRNewswire/ -- Indivior PLC (INDV.L) announces that the National Institutes of Health (NIH) has granted Indivior's application entitled "Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder" pursuant to Funding Opportunity Announcement RFA-DA-19-002 dedicated to the development of medications to prevent and treat opioid use disorder and overdose. Indivior's award is one of 375 grant awards across 41 states made by the NIH in fiscal year 2019 to apply scientific solutions to reverse the national opioid crisis.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Drugmaker Indivior Plc reported a 14% rise in quarterly profit on Wednesday, as its best-selling opioid addiction drug Suboxone lost market share to generic rivals at a slower pace than the company's previous modelling had expected. The maker of drugs that treat opioid addiction posted a pretax profit of $89 million in the second quarter ended June 30 from $78 million a year earlier. Revenue fell nearly 20% to $215 million in the quarter due to the expected decline in market share for Suboxone, but Indivior reaffirmed that it expects 2019 revenue to be between $670 million and $720 million.
SLOUGH, England and RICHMOND, Va. , July 31, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its first half 2019 results press release and investor supplement are now available via the ...
The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents. Suboxone film is applied below a patient's tongue, where it dissolves to release two active ingredients, buprenorphine and naloxone.
A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents. The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents.
SLOUGH, England and RICHMOND, Va. , July 11, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced revised expectations for FY 2019 net revenue and net income following stronger than expected H1 ...
The settlement, the largest by any company related to the U.S. opioid epidemic, resolved long-running probes by the U.S. Justice Department and the Federal Trade Commission into the companies' marketing and sales of Suboxone Film. The deal came after Indivior in April was indicted and accused of deceiving doctors and healthcare benefit programs into believing Suboxone Film, itself a form of opioid, was safer and less susceptible to abuse than similar drugs.
Britain's Reckitt Benckiser will pay up to $1.4 billion to resolve all U.S. federal investigations into the sales and marketing of an opioid addiction treatment by its former prescription pharmaceuticals business Indivior. Reckitt Benckiser (RB) said it had reached agreements with the U.S. Department of Justice (DOJ) and the Federal Trade Commission (FTC) to resolve the investigation into a business that was wholly demerged from the company in 2014. The U.S. Justice Department had accused Indivior of illegally boosting prescriptions for the opioid addiction treatment, called Suboxone Film.